Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT III concentrate.
Forty patients with preeclampsia were collected, and 27 of these cases were treated with AT III concentrate (1,000-2,000 units/day) for 7 days. According to an evaluation of objective clinical efficacy by the degree of improvement of GI scores in patients with preeclampsia, the number of effective cases was significantly greater among the treated groups than among the untreated groups (p less than 0.05). The rate of efficacy of the treated groups was 40%, compared with 0% in the untreated groups. In severe preeclampsia, a decrease in AT III activity was noted in 56.7%, a decrease in platelet count in 62.1%, and an increase in plasma FDP in 46.2%. A significant correlation was found between the GI score and the AT III activity. The anticoagulation therapy using AT III may normalize the chronic coagulation accelerated state in preeclampsia, and a good influence on the fetus may be expected.
Terao
T
T
Kobayashi
T
T
Imai
N
N
Oda
H
H
Karasawa
T
T
D000328:Adult; D000990:Antithrombin III / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000628:therapy*; D001780:Blood Coagulation Tests; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011446:Prospective Studies
D000990:Antithrombin III